EUVIMEDEUVIMED entdecken
Crossref

AB038. UK National Registry for thymic epithelial tumours: treatment patterns and survival outcomes

Eirini Konstantinidou, Eleni Josephides, Mariam Jallow, Marrika Colvin, Diluxshan Sritharan, Margaret Harris, Marie Eaton, Yvonne Summers, Deirdre Lynskey, Chloe Holmes, Matthew Evison, Maria Angeles Montero-Fernandez und 15 weitere

Mediastinum · 2026-10 · 10 · AB038-AB038

DOI: 10.21037/med-26-ab038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediastinum, 2026-10. Verfasst von Eirini Konstantinidou und 26 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thymic epithelial tumours (TETs) are rare mediastinal malignancies with heterogeneous biology and clinical course. Multi-institutional, real-world data describing treatment approaches and outcomes remain limited, prompting development of a UK National Registry reporting demographics, treatment patterns and survival outcomes. METHODS: We retrospectively analysed patients with TETs recorded in the UK National Registry, with data from 8 NHS Trusts (Guy’s & St Thomas’, The Christie, Cambridge University Hospitals, Royal Papworth, Manchester University Trust, Leeds Teaching Hospitals, NHS Greater Glasgow & Clyde, University Hospitals Sussex), diagnosed between April 2011 and August 2025. Disease was staged per TNM 8th edition. Overall survival (OS) and event-free survival (EFS) were estimated by Kaplan-Meier and log-rank methods. RESULTS: Among 620 patients (median age 64 years; 51.5% female; Stage I 69.4%, II 5.5%, III 5.0%, IV 12.1% and unknown 8%), 82.9% had thymoma, 14.0% thymic carcinoma and other 3.1%. Primary surgery was the first treatment in 76.5%, neoadjuvant chemotherapy (NACT) in 10.5%, palliative chemotherapy in 7.1%, radical radiotherapy in 1.5%; the remainder received palliative radiotherapy, surveillance or best supportive care. A total of 548 patients (88.4%) underwent surgical resection, with R0 resection in 64.8% (Stage I 72.8%, Stage II 60%, Stage III 42.9%, Stage IV 32.6%). Adjuvant radiotherapy was administered to 18.4% and adjuvant chemotherapy to 4.4%. Recurrence occurred in 10.1% of thymoma versus 34.5% of thymic carcinoma patients (P

Zitieren

APA

Konstantinidou, E., Josephides, E., Jallow, M., Colvin, M., Sritharan, D., Harris, M., Eaton, M., Summers, Y., Lynskey, D., Holmes, C., Evison, M., Montero-Fernandez, M. A., Bhatnagar, P., Datta, S., Robinson, S., Zaki, K., Hemelrijck, M. V., Ahmad, S., Smith, D., …, & Karapanagiotou, E. (2026). AB038. UK National Registry for thymic epithelial tumours: treatment patterns and survival outcomes. Mediastinum, 10, AB038-AB038. https://doi.org/10.21037/med-26-ab038

Vancouver

Konstantinidou E, Josephides E, Jallow M, Colvin M, Sritharan D, Harris M, et al. AB038. UK National Registry for thymic epithelial tumours: treatment patterns and survival outcomes. Mediastinum. 2026;10:AB038-AB038. doi:10.21037/med-26-ab038

BibTeX
@article{Konstantinidou2026,
  author = {Konstantinidou, Eirini and Josephides, Eleni and Jallow, Mariam and Colvin, Marrika and Sritharan, Diluxshan and Harris, Margaret and Eaton, Marie and Summers, Yvonne and Lynskey, Deirdre and Holmes, Chloe and Evison, Matthew and Montero-Fernandez, Maria Angeles and Bhatnagar, Pooja and Datta, Shalini and Robinson, Stephen and Zaki, Kam and Hemelrijck, Mieke Van and Ahmad, Shahreen and Smith, Daniel and Skwarski, Michael and Hughes, Daniel and Ghosh, Sharmistha and Gennatas, Spyridon and Georgiou, Alexandros and Young, Thomas and Bille, Andrea and Karapanagiotou, Eleni},
  title = {AB038. UK National Registry for thymic epithelial tumours: treatment patterns and survival outcomes},
  journal = {Mediastinum},
  year = {2026},
  volume = {10},
  pages = {AB038--AB038},
  doi = {10.21037/med-26-ab038}
}
Kostenlos starten →